Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis

References

• Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med. 2000;343(13):938–952.
   PubMed Web of Science ®Google Scholar
• Prevalence NMSSNYM, No title. 2004. [Online]. [cited 2017 Feb 16]. Available from: http://www.nationalmssociety.org/About-the-Society/MSPrevalence
   Google Scholar
• Tullman MJ. Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis. Am J Manag Care. 2013;19(2 Suppl):S15–20.
   PubMed Web of Science ®Google Scholar
• Ffrench-Constant C. Pathogenesis of multiple sclerosis. Lancet. 1994;343:271–275.
   PubMed Web of Science ®Google Scholar
• Hemler ME, Sanchez-Madrid F, Flotte TJ, et al. Glycoproteins of 210,000 and 130,000 m.w. on activated T cells: cell distribution and antigenic relation to components on resting cells and T cell lines. J Immunol. 1984;132(6):3011–3018.
   PubMed Web of Science ®Google Scholar
• Lobb R, Hemler M. The pathophysiologic role of alpha 4 integrins in vivo. J Clin Investig. 1994;94:1722–1728.
   PubMed Web of Science ®Google Scholar
• Baron JL, Madri JA, Ruddle NH, et al. Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med. 1993;177(1):57–68.
   PubMed Web of Science ®Google Scholar
• Elices M, Osborn L, Takada Y, et al. VCAM-1 on activated endothelium inter- acts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell. 1990;60:577–584.
   PubMed Web of Science ®Google Scholar
• Carlos TM, Schwartz BR, Kovach NL, et al. Vascular cell adhesion molecule-1 mediates lymphocyte adherence to cytokine-activated cultured human endothelial cells. Blood. 1990;76(5):965–970.
   PubMed Web of Science ®Google Scholar
• Yednock TA, Cannon C, Fritz LC, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature. 1992;356(6364):63–66.
   PubMed Web of Science ®Google Scholar
• Lutterotti A, Martin R. Getting specific: monoclonal antibodies in multiple sclerosis. Lancet Neurol. 2008;7(6):538–547.
   PubMed Web of Science ®Google Scholar
• Davis L, Oppenheimer-Marks N, Bednarczyk J, et al. Fibronectin promotes proliferation of naive and memory T cells by signaling through both the VLA-4 and VLA-5 integrin molecules. J Immunol. 1990 Aug 1;145(3):785–793
   Google Scholar
• Sheremata WA, Vollmer TL, Stone LA, et al. A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology. 1999 Mar;52(5):1072–1074.
   PubMed Web of Science ®Google Scholar
• European Medical Agency - summary of product characteristics. [Online]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Tysabri_20/European_Commission_final_decision/WC500202392.pdf. [cited 28 Feb 2017].
   Google Scholar
• Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003 Jan;348(1):15–23.
   PubMed Web of Science ®Google Scholar
• Stüve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol. 2006 May;59(5):743–747.
   PubMed Web of Science ®Google Scholar
• Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910.
   PubMed Web of Science ®Google Scholar
• Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911–923.
   PubMed Web of Science ®Google Scholar
• Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009;8(3):254–260.
   PubMed Web of Science ®Google Scholar
• Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005;353(4):375–381.
   PubMed Web of Science ®Google Scholar
• Kleinschmidt-DeMasters B, Tyler KL, Bkk-d N. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005;353:369–374.
   PubMed Web of Science ®Google Scholar
• van Assche G, van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med. 2005;353(4):362–368.
   Google Scholar
• Avasarala J. The TOUCH program and natalizumab: fundamental flaw in patient protection. F1000Res. 2016;4:1450.
   Google Scholar
• https://chefarztfrau.de/?page_id=716. [Online]. [cited 2017 Feb 16]. Available from: https://chefarztfrau.de/?page_id=716
   Google Scholar
• O’Connor P, Goodman A, Kappos L, et al. Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS study. Neurology. 2014;83(1):78–86.
   PubMed Web of Science ®Google Scholar
• Butzkueven H, Kappos L, Pellegrini F, et al. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. J Neurol Neurosurg Psychiatry. 2014;0:1–8.
   Google Scholar
• Antezana A, Sigal S, Herbert J, et al. Natalizumab-induced hepatic injury: a case report and review of literature. Mult Scler Relat Disord. 2015;4(6):495–498.
   PubMed Web of Science ®Google Scholar
• Fagius J, Burman J. Normal outcome of pregnancy with ongoing treatment with natalizumab. Acta Neurol Scand. 2014;129:e27–e29.
   PubMed Web of Science ®Google Scholar
• Schneider H, Weber CE, Hellwig K, et al. Natalizumab treatment during pregnancy - effects on the neonatal immune system. Acta Neurol Scand. 2012;127(1):e1-4.
   PubMed Web of Science ®Google Scholar
• Haghikia A, Langer-Gould A, Rellensmann G, et al. Natalizumab use during the third trimester of pregnancy. JAMA Neurol. 2014;71(7):891–895.
   PubMed Web of Science ®Google Scholar
• Lu E, Wang BW, Guimond C, et al. Disease-Modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology. 2012;79(11):1130–1135.
   PubMed Web of Science ®Google Scholar
• Ebrahimi N, Herbstritt S, Gold R, et al. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study. Mult Scler. 2015;21(2):198–205.
   PubMed Web of Science ®Google Scholar
• Leroy C, Rigot J-M, Leroy M, et al. Immunosuppressive drugs and fertility. Orphanet J Rare Dis. 2015;10(1):136.
   PubMed Web of Science ®Google Scholar
• Buraga I, Popovici RE. Multiple sclerosis and pregnancy: current considerations. Sci World J. 2014;2014:1–6.
   Web of Science ®Google Scholar
• Amato MP, Portaccio E. Fertility, pregnancy and childbirth in patients with multiple sclerosis: impact of disease-modifying drugs. CNS Drugs. 2015;29(3):207–220.
   PubMed Web of Science ®Google Scholar
• Baldwin KJ, Hogg JP. Progressive multifocal leukoencephalopathy in patients with multiple sclerosis. Curr Opin Neurol. 2013;26(3):318–323.
   PubMed Web of Science ®Google Scholar
• Sørensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler. 2012;18(2):143–152.
   PubMed Web of Science ®Google Scholar
• Ferenczy MW, Marshall LJ, Nelson CD, et al. Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev. 2012;25(3):471–506.
   PubMed Web of Science ®Google Scholar
• Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol. 2010;9(4):425–437.
   PubMed Web of Science ®Google Scholar
• Sabath BF, Major EO. Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy. J Infect Dis. 2002;186(Suppl):S180–6.
   PubMed Web of Science ®Google Scholar
• Chesters PM, Heritage J, McCance DJ. Persistence of DNA sequences of BK virus and JC virus in normal human tissues and in diseased tissues. J Infect Dis. 1983;147(4):676–684.
   PubMed Web of Science ®Google Scholar
• Monaco MC, Atwood WJ, Gravell M, et al. JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency. J Virol. 1996;70(10):7004–7012.
   PubMed Web of Science ®Google Scholar
• Berger JR, Major EO. Progressive multifocal leukoencephalopathy. Semin Neurol. 1999;19(2):193–200.
   PubMed Web of Science ®Google Scholar
• Ledoux S, Libman I, Robert F, et al. Progressive multifocal leukoencephalopathy with gray matter involvement. Can J Neurol Sci. 1989;16:200–202.
   PubMed Web of Science ®Google Scholar
• Richardson EP, Webster HD. Progressive multifocal leukoencephalopathy: its pathological features. Prog Clin Biol Res. 1983;105:191–203.
   PubMedGoogle Scholar
• Du Pasquier RA, Corey S, Margolin DH, et al. Productive infection of cerebellar granule cell neurons by JC virus in an HIV+ individual. Neurology. 2003;61(6):775–782.
   PubMed Web of Science ®Google Scholar
• Wüthrich C, Dang X, Westmoreland S, et al. Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons. Ann Neurol. 2009;65(6):742–748.
   PubMed Web of Science ®Google Scholar
• Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: consensus statement from the AAN neuroinfectious disease section. Neurology. 2013;80(15):1430–1438.
   PubMed Web of Science ®Google Scholar
• Mentzer D, Prestel J, Adams O, et al. Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies. J Neurol Neurosurg Psychiatry. 2012;83(9):927–933.
   PubMed Web of Science ®Google Scholar
• Cinque P, Koralnik IJ, Gerevini S, et al. Progressive multifocal leukoencephalopathy in HIV-1 infection. Lancet Infect Dis. 2009;9(10):625–636.
   PubMed Web of Science ®Google Scholar
• Clifford DB, de Luca A, DeLuca A, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010;9(4):438–446.
   PubMed Web of Science ®Google Scholar
• Sudhakar P, Bachman DM, Mark AS, et al. Progressive multifocal leukoencephalopathy: recent advances and a neuro-ophthalmological review. J Neuroophthalmol. 2015;35(3):296–305.
   PubMed Web of Science ®Google Scholar
• Khoury MN, Alsop DC, Agnihotri SP, et al. Hyperintense cortical signal on magnetic resonance imaging reflects focal leukocortical encephalitis and seizure risk in progressive multifocal leukoencephalopathy. Ann Neurol. 2014;75(5):659–669.
   PubMed Web of Science ®Google Scholar
• Antinori A, Ammassari A, Giancola ML, et al. Epidemiology and prognosis of AIDS-associated progressive multifocal leukoencephalopathy in the HAART era. J Neurovirol. 2001;7(4):323–328.
   PubMed Web of Science ®Google Scholar
• Casado JL, Corral I, García J, et al. Continued declining incidence and improved survival of progressive multifocal leukoencephalopathy in HIV/AIDS patients in the current era. Eur J Clin Microbiol Infect Dis. 2014;33(2):179–187.
   PubMed Web of Science ®Google Scholar
• Plavina T, Subramanyam M, Bloomgren G, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2014;76(6):802–812.
   PubMed Web of Science ®Google Scholar
• EMA confirms recommendations to minimise risk of brain infection PML with Tysabri - EMA/137488/2016 [cited 2016 Feb 26]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2016/02/WC500202389.pdf
   Google Scholar
• European Medicines Agency. European Medicines Agency recommends additional measures to better manage risk of progressive multifocal leukoencephalopathy (PML) with Tysabri. [Online]. [cited 28 Feb 2017]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/01/news_detail_000987.jsp&mid=WC0b01ac058004d5c1
   Google Scholar
• Honce JM, Nagae L, Nyberg E. Neuroimaging of natalizumab complications in multiple sclerosis: PML and other associated entities. Mult Scler Int. 2015;2015:809252.
   PubMedGoogle Scholar
• McGuigan C, Craner M, Guadagno J, et al. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry. 2016;87(2):117–125.
   PubMed Web of Science ®Google Scholar
• Yousry TA, Pelletier D, Cadavid D, et al. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2012;72(5):779–787.
   PubMed Web of Science ®Google Scholar
• Wattjes MP, Vennegoor A, Steenwijk MD, et al. MRI pattern in asymptomatic natalizumab-associated PML. J Neurol Neurosurg Psychiatry. 2015 Jul;86(7):793–798.
   PubMed Web of Science ®Google Scholar
• Blair NF, Brew BJ, Halpern JP. Natalizumab-associated PML identified in the presymptomatic phase using MRI surveillance. Neurology. 2012;78(7):507–508.
   PubMed Web of Science ®Google Scholar
• Murdoch DM, Venter WD, van Rie A, et al. Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options. AIDS Res Ther. 2007;4(1):9.
   PubMedGoogle Scholar
• Shelburne SA, Visnegarwala F, Darcourt J, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. Aids. 2005;19(4):399–406.
   PubMed Web of Science ®Google Scholar
• Lipman M, Breen R. Immune reconstitution inflammatory syndrome in HIV 77. Curr Opin Infect Dis. 2006;19(0951–7375 (Print)):20–25.
   PubMed Web of Science ®Google Scholar
• Tan K, Roda R, Ostrow L, et al. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology. 2009;72(17):1458–1464.
   PubMed Web of Science ®Google Scholar
• Huang D, Cossoy M, Li M, et al. Inflammatory progressive multifocal leukoencephalopathy in human immunodeficiency virus-negative patients. Ann Neurol. 2007;62(1):34–39.
   PubMed Web of Science ®Google Scholar
• Pavlovic D, Patera AC, Nyberg F, et al. Progressive multifocal leukoencephalopathy: current treatment options and future perspectives. Ther Adv Neurol Disord. 2015;8(6):255–273.
   PubMed Web of Science ®Google Scholar
• Khatri BO, Man S, Giovannoni G, et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology. 2009;72(5):402–409.
   PubMed Web of Science ®Google Scholar
• Subramanyam M, Plavina T, Khatri BO, et al. The effect of plasma exchange on serum anti-JC virus antibodies. Mult Scler. 2013;19(7):912–919.
   PubMed Web of Science ®Google Scholar
• Elphick GF, Querbes W, Jordan JA, et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science. 2004;306(5700):1380–1383.
   PubMed Web of Science ®Google Scholar
• Aksamit AJ, Progressive multifocal leukoencephalopathy Infectious Disease. Continuum (Minneap. Minn). 2012;18(6):1374–1391.
   PubMedGoogle Scholar
• Epperla N, Medina-Flores R, Mazza JJ. Drugs smarter than the bugs: mirtazapine and mefloquine therapy for non-aids related progressive multifocal leukoencephalopathy. J Gen Intern Med. 2013;28:S318–S319.
   Web of Science ®Google Scholar
• Park JH, Ryoo S, Noh HJ, et al. Dual therapy with cidofovir and mirtazapine for progressive multifocal leukoencephalopathy in a sarcoidosis patient. Case Rep Neurol. 2011;3(3):258–262.
   PubMedGoogle Scholar
• Verma S, Cikurel K, Koralnik IJ, et al. Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia vera. J Infect Dis. 2007;196(5):709–711.
   PubMed Web of Science ®Google Scholar
• Cettomai D, McArthur JC. Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy. Arch Neurol. 2009;66(2):255–258.
   PubMed Web of Science ®Google Scholar
• Kast RE, Focosi D, Petrini M, et al. Treatment schedules for 5-HT2A blocking in progressive multifocal leukoencephalopathy using risperidone or ziprasidone. Bone Marrow Transplant. 2007 Jun;39(12):811–812.
   PubMed Web of Science ®Google Scholar
• Brickelmaier M, Lugovskoy A, Kartikeyan R, et al. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother. 2009;53(5):1840–1849.
   PubMed Web of Science ®Google Scholar
• Clifford DB, Nath A, Cinque P, et al. A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes. J Neurovirol. 2013;19(4):351–358.
   PubMed Web of Science ®Google Scholar
• Wattjes MP, Killestein J. Progressive multifocal leukoencephalopathy after natalizumab discontinuation: few and true? Ann Neurol. 2014 Mar;75(3):462–462.
   PubMed Web of Science ®Google Scholar
• Prosperini L, de Rossi N, Scarpazza C, et al. Natalizumab-related progressive multifocal leukoencephalopathy in multiple sclerosis: findings from an Italian independent registry. Plos One. 2016;11(12):e0168376.
   PubMed Web of Science ®Google Scholar
• Tan IL, McArthur JC, Clifford DB, et al. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology. 2011;77(11):1061–1067.
   PubMed Web of Science ®Google Scholar
• De Rossi N, Cordioli C, Gerevini S, et al. MS Italian patients manifesting natalizumab-related PML between 2009 and 2014. Report of the Italian group for MS-PML. Mult Scler J. 2015;21:596–597.
   Google Scholar
• Landi D, De Rossi N, Zagaglia S, et al. No evidence of beneficial effect of plasmapheresis (PLEX) in natalizumab associated PML: pooled analysis of Italian and published international cases. Neurol Sci.2016;37:148.
   Google Scholar
• ClinicSpeak, Natalizumab PML update - Q4 2014, January 2015. [Online]. [cited 16 Feb 2017]. Available from: http://multiple-sclerosis-research.blogspot.com/2015/01/clinicspeak-natalizumab-pml-update-q4.html
   Google Scholar
• Vermersch P, Kappos L, Gold R, et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology. 2011;76(20):1697–1704.
   PubMed Web of Science ®Google Scholar
• Vitaliti G, Matin N, Tabatabaie O, et al. Natalizumab in multiple sclerosis: discontinuation, progressive multifocal leukoencephalopathy and possible use in children. Expert Rev Neurother. 2015;15(11):1321–1341.
   PubMed Web of Science ®Google Scholar
• Na A, Hall N, Kavar B, et al. Central nervous system lymphoma associated with natalizumab. J Clin Neurosci. 2014;21(6):1068–1070.
   PubMed Web of Science ®Google Scholar
• Bozic C, LaGuette J, Panzara MA, et al. Natalizumab and central nervous system lymphoma: no clear association. Ann Neurol. 2009 Sep;66(3):261–262.
   PubMed Web of Science ®Google Scholar
• Schowinsky J, Corboy J, Vollmer T, et al. Natalizumab-associated complication? First case of peripheral T cell lymphoma. Acta Neuropathol. 2012 May;123(5):751–752.
   PubMed Web of Science ®Google Scholar
• Laroni A, Bedognetti M, Uccelli A, et al. Association of melanoma and natalizumab therapy in the Italian MS population: a second case report. Neurol Sci. 2011 Feb;32(1):181–182.
   PubMed Web of Science ®Google Scholar
• Pharaon M, Tichet M, Lebrun-Frénay C, et al. Risk for nevus transformation and melanoma proliferation and invasion during natalizumab treatment: four years of dermoscopic follow-up with immunohistological studies and proliferation and invasion assays. JAMA Dermatol. 2014 Aug;150(8):901–903.
   PubMed Web of Science ®Google Scholar
• Rolfes L, Lokhorst B, Samijn J, et al. Cervical dysplasia associated with the use of natalizumab. Neth J Med. 2013 Nov;71(9):494–495.
   PubMed Web of Science ®Google Scholar
• O’Connor PW. ‘Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis’: author response. Neurology. 2011;77(21):1930–1931.
   PubMedGoogle Scholar
• Berger JR, Centonze D, Comi G, et al. Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. Ann Neurol. 2010 Sep;68(3):409–411.
   PubMed Web of Science ®Google Scholar
• Sangalli F, Moiola L, Ferrè L, et al. Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients. Mult Scler Relat Disord. 2014;3(4):520–526.
   PubMed Web of Science ®Google Scholar
• Killestein J, Vennegoor A, Strijbis EM, et al. Natalizumab drug holiday in multiple sclerosis: poorly tolerated. Ann Neurol. 2010 Sep;68(3):392–395.
   PubMed Web of Science ®Google Scholar
• Clerico M, Schiavetti I, de Mercanti SF, et al. Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP study). JAMA Neurol. 2014;71(8):954–960.
   PubMed Web of Science ®Google Scholar
• Lo RM, Capobianco M, Ragonese P, et al. Natalizumab discontinuation and treatment strategies in patients with multiple sclerosis (MS): a retrospective study from two Italian MS centers. Neurol Ther. 2015 Dec;4(2):147–157.
   PubMedGoogle Scholar
• Papeix C, Vukusic S, Casey R, et al. Risk of relapse after natalizumab withdrawal: results from the French TYSEDMUS cohort. Neurol Neuroimmunol Neuroinflammation. 2016 Dec;3(6):e297.
   PubMed Web of Science ®Google Scholar
• Weinstock-Guttman B, Hagemeier J, Kavak KS, et al. Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation. J Neurol Neurosurg Psychiatry. 2016;87(9):937–943. jnnp-2015-312221.
   Web of Science ®Google Scholar
• Borriello G, Prosperini L, Mancinelli C, et al. Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study. Eur J Neurol. 2012;19(5):783–787.
   PubMed Web of Science ®Google Scholar
• Evangelopoulos ME, Koutoulidis V, Andreadou E, et al. Pulsed corticosteroid treatment in MS patients stabilizes disease activity following natalizumab withdrawal prior to switching to fingolimod. Int J Neurosci. 2016 Dec;126(12):1097–1102.
   PubMed Web of Science ®Google Scholar
• Alping P, Frisell T, Novakova L, et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Ann Neurol. 2016;79(6):950–958.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Turner B, Gnanapavan S, et al. Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Mult Scler Relat Disord. 2015 Jul;4(4):329–333.
   PubMed Web of Science ®Google Scholar
• Outteryck O, Ongagna JC, Brochet B, et al. A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort. Eur J Neurol. 2014;21(1):40–48.
   PubMed Web of Science ®Google Scholar
• Sangalli F, Moiola L, Bucello S, et al. Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study. Neurological Sci. 2011;31(S3):299–302.
   PubMed Web of Science ®Google Scholar
• Tavazzi E, White MK, Khalili K. Progressive multifocal leukoencephalopathy: clinical and molecular aspects. Rev Med Virol. 2012;22(1):18–32.
   PubMed Web of Science ®Google Scholar
• No title. [Online]. [cited 2017 Feb 16]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Tysabri_20/Opinion_provided_by_Committee_for_Medicinal_Products_for_Human_Use/WC500203426.pdf
   Google Scholar